{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:37:47Z","timestamp":1792420667399,"version":"4.5.0"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1038\/s41581-023-00801-1","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:09:39Z","timestamp":1706184579000},"page":"330-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The changing landscape of HIV-associated kidney disease"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6461-8609","authenticated-orcid":false,"given":"Nina E.","family":"Diana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7058-9725","authenticated-orcid":false,"given":"Saraladevi","family":"Naicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"801_CR1","unstructured":"UNAIDS. In Danger: UNAIDS Global AIDS Update 2022 https:\/\/www.unaids.org\/en\/resources\/documents\/2022\/in-danger-global-aids-update (Joint United Nations Programme on HIV\/AIDS, 2022)."},{"key":"801_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJM198403153101101","volume":"310","author":"TK Rao","year":"1984","unstructured":"Rao, T. K. et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 310, 669\u2013673 (1984).","journal-title":"N. Engl. J. Med."},{"key":"801_CR3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/ki.1989.135","volume":"35","author":"V D\u2019Agati","year":"1989","unstructured":"D\u2019Agati, V., Suh, J. I., Carbone, L., Cheng, J. T. & Appel, G. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 35, 1358\u20131370 (1989).","journal-title":"Kidney Int."},{"key":"801_CR4","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.kint.2020.01.018","volume":"97","author":"S Kudose","year":"2020","unstructured":"Kudose, S. et al. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int. 97, 1006\u20131016 (2020).","journal-title":"Kidney Int."},{"key":"801_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269260","volume":"17","author":"NE Diana","year":"2022","unstructured":"Diana, N. E. et al. Clinicopathological correlation of kidney disease in HIV infection pre- and post-ART rollout. PLoS One 17, e0269260 (2022).","journal-title":"PLoS One"},{"key":"801_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ijantimicag.2017.04.021","volume":"50","author":"AC Achhra","year":"2017","unstructured":"Achhra, A. C. et al. Impact of early versus deferred antiretroviral therapy of estimated glomerular filtration rate in HIV-positive individuals in the START trial. Int. J. Antimicrob. Agents 50, 453\u2013460 (2017).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"801_CR7","first-page":"363","volume":"18","author":"PG Stock","year":"2010","unstructured":"Stock, P. G. et al. Outcomes of kidney transplantation in HIV-infected recipients. N. Engl. J. Med. 18, 363 (2010). Erratum in: N Engl J Med. 364, 1082 (2011).","journal-title":"N. Engl. J. Med."},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1097\/TP.0000000000003485","volume":"105","author":"E Muller","year":"2021","unstructured":"Muller, E. et al. Kidney transplantation in HIV-positive patients: current practice and management strategies. Transplantation 105, 1492\u20131501 (2021).","journal-title":"Transplantation"},{"key":"801_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.7326\/0003-4819-139-3-200308050-00011","volume":"139","author":"PL Kimmel","year":"2003","unstructured":"Kimmel, P. L., Barisoni, L. & Kopp, J. B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann. Intern. Med. 139, 214\u2013226 (2003).","journal-title":"Ann. Intern. Med."},{"key":"801_CR10","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1093\/ndt\/gfr676","volume":"27","author":"FX Lescure","year":"2012","unstructured":"Lescure, F. X. et al. HIV-associated kidney glomerular diseases: changes with time and HAART. Nephrol. Dial. Transpl. 27, 2349\u20132355 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"801_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.kint.2017.11.007","volume":"93","author":"CR Swanepoel","year":"2018","unstructured":"Swanepoel, C. R. et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 93, 545\u2013559 (2018).","journal-title":"Kidney Int."},{"key":"801_CR12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.ekir.2023.02.1076","volume":"8","author":"N Wearne","year":"2023","unstructured":"Wearne, N. et al. The evolving spectrum of kidney histology in HIV positive patients in South Africa. Kidney Int. Rep. 8, 1087\u20131096 (2023).","journal-title":"Kidney Int. Rep."},{"key":"801_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ki.2014.44","volume":"86","author":"SK Mallipattu","year":"2014","unstructured":"Mallipattu, S. K., Salem, F. & Wyatt, C. M. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int. 86, 259\u2013265 (2014).","journal-title":"Kidney Int."},{"key":"801_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.semnephrol.2008.08.005","volume":"28","author":"CM Wyatt","year":"2008","unstructured":"Wyatt, C. M., Klotman, P. E. & D\u00c1gati, V. D. HIV-associated nephropathy: clinical presentation, pathology and epidemiology in the era of antiretroviral therapy. Semin. Nephrol. 28, 513\u2013522 (2008).","journal-title":"Semin. Nephrol."},{"key":"801_CR15","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3390\/jcm8081254","volume":"8","author":"G Alfano","year":"2019","unstructured":"Alfano, G. et al. Kidney disease in HIV infection. J. Clin. Med. 8, 1254 (2019).","journal-title":"J. Clin. Med."},{"key":"801_CR16","doi-asserted-by":"publisher","first-page":"aaf6925","DOI":"10.1126\/sciimmunol.aaf6925","volume":"1","author":"R Remark","year":"2016","unstructured":"Remark, R. et al. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Sci. Immunol. 1, aaf6925 (2016).","journal-title":"Sci. Immunol."},{"key":"801_CR17","doi-asserted-by":"publisher","first-page":"aaa0698","DOI":"10.1126\/science.aaa0698","volume":"348","author":"GJ Xu","year":"2015","unstructured":"Xu, G. J. et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science 348, aaa0698 (2015).","journal-title":"Science"},{"key":"801_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1056\/NEJM199209033271006","volume":"327","author":"PL Kimmel","year":"1992","unstructured":"Kimmel, P. L. et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N. Engl. J. Med. 327, 702\u2013706 (1992).","journal-title":"N. Engl. J. Med."},{"key":"801_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/ki.1993.386","volume":"44","author":"PL Kimmel","year":"1993","unstructured":"Kimmel, P. L. et al. HIV-associated immune-mediated renal disease. Kidney Int. 44, 1327\u20131340 (1993).","journal-title":"Kidney Int."},{"key":"801_CR20","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/sj.ki.5000351","volume":"69","author":"TE Gerntholtz","year":"2006","unstructured":"Gerntholtz, T. E., Goetsch, S. J. & Katz, I. HIV-related nephropathy: a South African perspective. Kidney Int. 69, 1885\u20131891 (2006).","journal-title":"Kidney Int."},{"key":"801_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.7196\/SAMJ.2019.v109i7.13644","volume":"109","author":"A Vermeulen","year":"2019","unstructured":"Vermeulen, A. et al. Patterns of renal disease: a 30-year renal biopsy study at Chris Hani Baragwanath Academic Hospital, Soweto, Johannesburg, South Africa. S Afr. Med. J. 109, 486\u2013492 (2019).","journal-title":"S Afr. Med. J."},{"key":"801_CR22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/sj.ki.5000292","volume":"69","author":"R Nair","year":"2006","unstructured":"Nair, R., Walker, P. D. & Is, I. G. A nephropathy the commonest primary glomerulopathy among your adults in the USA? Kidney Int. 69, 1455\u20131458 (2006).","journal-title":"Kidney Int."},{"key":"801_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/jmv.24353","volume":"88","author":"F Fabrizi","year":"2016","unstructured":"Fabrizi, F. et al. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis. J. Med. Virol. 88, 487\u2013497 (2016).","journal-title":"J. Med. Virol."},{"key":"801_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040245","volume":"7","author":"A Mocroft","year":"2012","unstructured":"Mocroft, A. et al. Hepatitis B and co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 7, e40245 (2012).","journal-title":"PLoS One"},{"key":"801_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/nep.13564","volume":"24","author":"B Davidson","year":"2019","unstructured":"Davidson, B. et al. Granulomatous interstitial nephritis on renal biopsy in human immunodeficiency virus positive patients: prevalence and causes in Cape Town, South Africa. Nephrology 24, 681\u2013688 (2019).","journal-title":"Nephrology"},{"key":"801_CR26","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1016\/j.jacc.2017.05.012","volume":"69","author":"A Kearns","year":"2017","unstructured":"Kearns, A., Gordon, J., Burdo, T. H. & Qin, X. HIV-1-associated atherosclerosis: unraveling the missing link. J. Am. Coll. Cardiol. 69, 3084\u20133098 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"801_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cca.2012.11.025","volume":"416","author":"H Ipp","year":"2013","unstructured":"Ipp, H. & Zemlin, A. The paradox of the immune response in HIV infection: when inflammation becomes harmful. Clin. Chim. Acta 416, 96\u201399 (2013).","journal-title":"Clin. Chim. Acta"},{"key":"801_CR28","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/infdis\/jis545","volume":"206","author":"T Kelesidis","year":"2012","unstructured":"Kelesidis, T., Kendall, M. A., Yang, O. O., Hodis, H. N. & Currier, J. S. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J. Infect. Dis. 206, 1558\u20131567 (2012).","journal-title":"J. Infect. Dis."},{"key":"801_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063804","volume":"8","author":"ML Alcaide","year":"2013","unstructured":"Alcaide, M. L. et al. Immune activation in HIV-infected aging women on antiretrovirals-implications for age-associated comorbidities: a cross-sectional pilot study. PLoS One 8, e63804 (2013).","journal-title":"PLoS One"},{"key":"801_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12035-014-8991-3","volume":"53","author":"R Ma","year":"2016","unstructured":"Ma, R., Yang, L., Niu, F. & Buch, S. HIV Tat-mediated induction of human brain microvascular endothelial cell apoptosis involves endoplasmic reticulum stress and mitochondrial dysfunction. Mol. Neurobiol. 53, 132\u2013142 (2016).","journal-title":"Mol. Neurobiol."},{"key":"801_CR31","doi-asserted-by":"publisher","first-page":"21716","DOI":"10.1074\/jbc.M114.566620","volume":"289","author":"H Guo","year":"2014","unstructured":"Guo, H., Gao, J., Taxman, D. J., Ting, J. P. & Su, L. HIV-1 infection induces interleukin-1\u03b2 production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. J. Biol. Chem. 289, 21716\u201321726 (2014).","journal-title":"J. Biol. Chem."},{"key":"801_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000353902","volume":"57","author":"JC Hernandez","year":"2014","unstructured":"Hernandez, J. C., Latz, E. & Urcuqui-Inchima, S. HIV-1 induces the first signal to activate the NLRP3 inflammasome in monocyte-derived macrophages. Intervirology 57, 36\u201342 (2014).","journal-title":"Intervirology"},{"key":"801_CR33","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","volume":"165","author":"TT Brown","year":"2005","unstructured":"Brown, T. T. et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch. Intern. Med. 165, 1179\u20131184 (2005).","journal-title":"Arch. Intern. Med."},{"key":"801_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223224","volume":"14","author":"JE Heron","year":"2019","unstructured":"Heron, J. E. et al. The prevalence and risk of non-infectious comorbidities in HIV infected and non-HIV infected men attending general practice in Australia. PLoS One 14, e0223224 (2019).","journal-title":"PLoS One"},{"key":"801_CR35","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1097\/QAI.0000000000002798","volume":"88","author":"J H\u00f8gh","year":"2021","unstructured":"H\u00f8gh, J. et al. HIV infection as associated with type 2 diabetes mellitus. J. Acquir. Immune Defic. Syndr. 88, e32\u2013e35 (2021).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"801_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11892-018-1076-3","volume":"18","author":"EC Noubissi","year":"2018","unstructured":"Noubissi, E. C., Katte, J. C. & Sobngwi, E. Diabetes and HIV. Curr. Diab Rep. 18, 125 (2018).","journal-title":"Curr. Diab Rep."},{"key":"801_CR37","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/ki.2012.445","volume":"83","author":"SK Mallipattu","year":"2013","unstructured":"Mallipattu, S. K. et al. Expression of HIV transgene aggravates kidney injury in diabetic mice. Kidney Int. 83, 626\u2013634 (2013).","journal-title":"Kidney Int."},{"key":"801_CR38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/hiv.13375","volume":"24","author":"TE Gooden","year":"2023","unstructured":"Gooden, T. E. et al. A matched cohort study investigating premature, accentuated, and accelerated aging in people living with HIV. HIV Med. 24, 640\u2013647 (2023).","journal-title":"HIV Med."},{"key":"801_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/ncpneph0990","volume":"5","author":"S Cohen","year":"2009","unstructured":"Cohen, S. & Kimmel, P. Renal biopsy is necessary for the diagnosis of HIV-associated renal diseases. Nat. Rev. Nephrol. 5, 22\u201323 (2009).","journal-title":"Nat. Rev. Nephrol."},{"key":"801_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/ki.2009.115","volume":"76","author":"AA Soler-Garc\u00eda","year":"2009","unstructured":"Soler-Garc\u00eda, A. A., Rakhmanina, N. Y., Mattison, P. C. & Ray, P. E. A urinary biomarker profile for children with HIV-associated renal diseases. Kidney Int. 76, 207\u2013214 (2009).","journal-title":"Kidney Int."},{"key":"801_CR41","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1681\/ASN.2009010065","volume":"20","author":"N Paragas","year":"2009","unstructured":"Paragas, N. et al. Urinary NGAL marks cystic disease in HIV-associated nephropathy. J. Am. Soc. Nephrol. 20, 1687\u20131692 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR42","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1093\/ndt\/gfr258","volume":"26","author":"DA Sola-Del Valle","year":"2011","unstructured":"Sola-Del Valle, D. A. et al. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol. Dial. Transpl. 26, 2387\u20132390 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"key":"801_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/IJNRD.S331484","volume":"14","author":"S Naicker","year":"2021","unstructured":"Naicker, S. et al. Profiling biomarkers in HIV glomerular disease \u2014 potential for the non-invasive diagnosis of HIVAN? Int. J. Nephrol. Renovasc Dis. 14, 427\u2013440 (2021).","journal-title":"Int. J. Nephrol. Renovasc Dis."},{"key":"801_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/FTD.0000000000000589","volume":"41","author":"BR Griffin","year":"2019","unstructured":"Griffin, B. R., Faubel, S. & Edelstein, C. L. Biomarkers of drug-induced kidney toxicity. Ther. Drug. Monit. 41, 213\u2013226 (2019).","journal-title":"Ther. Drug. Monit."},{"key":"801_CR45","doi-asserted-by":"publisher","first-page":"1501785","DOI":"10.1155\/2016\/1501785","volume":"2016","author":"T Fiseha","year":"2016","unstructured":"Fiseha, T. & Gebreweld, A. Urinary markers of tubular injury in HIV-infected patients. Biochem. Res. Int. 2016, 1501785 (2016).","journal-title":"Biochem. Res. Int."},{"key":"801_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/QAI.0b013e3182737706","volume":"61","author":"MG Shlipak","year":"2012","unstructured":"Shlipak, M. G. et al. Urinary markers of kidney injury and kidney function decline in HIV-infected women. J. Acquir. Immune Defic. Syndr. 61, 565\u2013573 (2012).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"801_CR47","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/QAI.0b013e31826a6c4f","volume":"61","author":"LA Inker","year":"2012","unstructured":"Inker, L. A. et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV population on antiretrovirals. J. Acquir. Immune Defic. Syndr. 61, 302\u2013309 (2012).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"801_CR48","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/QAD.0b013e32835fac30","volume":"27","author":"A Gagneux-Brunon","year":"2013","unstructured":"Gagneux-Brunon, A. et al. Performance of creatinine and cystatin C-based glomerular filtration rate estimation equations in a European HIV-positive cohort. AIDS 27, 1573\u20131581 (2013).","journal-title":"AIDS"},{"key":"801_CR49","unstructured":"European AIDS Clinical Society guidelines Oct 2021. https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/ (accessed January 2023)."},{"key":"801_CR50","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med"},{"key":"801_CR51","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/j.ajkd.2021.03.008","volume":"78","author":"C Degado","year":"2021","unstructured":"Degado, C. et al. Reassessing the inclusion of race in diagnosing kidney diseases: an interim report from the NKF-ASN Task Force. Am. J. Kidney Dis. 78, 103\u2013115 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"801_CR52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","volume":"79","author":"C Degado","year":"2022","unstructured":"Degado, C. et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am. J. Kidney Dis. 79, 268\u2013288.e1 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"801_CR53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/cid\/ciac731","volume":"76","author":"AN Muiru","year":"2023","unstructured":"Muiru, A. N. et al. Effect of adopting the new race-free 2021 chronic kidney disease epidemiology collaboration estimated glomerular filtration rate creatinine equation on racial differences in kidney disease progression among people with human immunodeficiency virus: an observational study. Clin. Infect. Dis. 76, 461\u2013468 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"801_CR54","doi-asserted-by":"publisher","first-page":"e1159","DOI":"10.1016\/S2214-109X(22)00239-X","volume":"10","author":"J Fabian","year":"2022","unstructured":"Fabian, J. et al. Measurement of kidney function in Malawi, South Africa, and Uganda: a multicenter cohort study. Lancet Glob. Health 10, e1159\u2013e1169 (2022).","journal-title":"Lancet Glob. Health"},{"key":"801_CR55","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker, L. A. et al. New creatinine-and cystatin C\u2013based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737\u20131749 (2021).","journal-title":"N. Engl. J. Med."},{"key":"801_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215630","volume":"14","author":"B Bhasin","year":"2019","unstructured":"Bhasin, B. et al. Correction: HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C. PLoS One 14, e0215630 (2019).","journal-title":"PLoS One"},{"key":"801_CR57","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1681\/ASN.V11112079","volume":"11","author":"LA Bruggeman","year":"2000","unstructured":"Bruggeman, L. A. et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J. Am. Soc. Nephrol. 11, 2079\u20132087 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR58","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nm0502-522","volume":"8","author":"D Marras","year":"2002","unstructured":"Marras, D. et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat. Med. 8, 522\u2013526 (2002).","journal-title":"Nat. Med."},{"key":"801_CR59","doi-asserted-by":"publisher","first-page":"e01718","DOI":"10.1128\/JVI.01718-17","volume":"92","author":"EH Payne","year":"2018","unstructured":"Payne, E. H., Ramalingam, D., Fox, D. T. & Klotman, M. E. Polyploidy and mitotic cell death are two distinct HIV-1 Vpr-driven outcomes in renal tubule epithelial cells. J. Virol. 92, e01718\u201317 (2018).","journal-title":"J. Virol."},{"key":"801_CR60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1172\/JCI119525","volume":"100","author":"LA Bruggeman","year":"1997","unstructured":"Bruggeman, L. A. et al. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J. Clin. Invest. 100, 84\u201392 (1997).","journal-title":"J. Clin. Invest."},{"key":"801_CR61","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1097\/01.ASN.0000019642.55998.69","volume":"13","author":"M Husain","year":"2002","unstructured":"Husain, M. et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J. Am. Soc. Nephrol. 13, 1806\u20131815 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR62","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0042-6822(91)90759-5","volume":"185","author":"P Dickie","year":"1991","unstructured":"Dickie, P. et al. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 185, 109\u2013119 (1991).","journal-title":"Virology"},{"key":"801_CR63","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1681\/ASN.2005080878","volume":"17","author":"Y Zuo","year":"2006","unstructured":"Zuo, Y. et al. HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J. Am. Soc. Nephrol. 17, 2832\u20132843 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0002-9440(10)64156-9","volume":"61","author":"PG Conaldi","year":"2002","unstructured":"Conaldi, P. G. et al. Human immunodeficiency virus-1 tat induces hyperproliferation and dysregulation of renal glomerular epithelial cells. Am. J. Pathol. 61, 53\u201361 (2002).","journal-title":"Am. J. Pathol."},{"key":"801_CR65","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJM200106283442604","volume":"344","author":"JA Winston","year":"2001","unstructured":"Winston, J. A. et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N. Engl. J. Med. 344, 1979\u20131984 (2001).","journal-title":"N. Engl. J. Med."},{"key":"801_CR66","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1146\/annurev.immunol.18.1.665","volume":"18","author":"T Pierson","year":"2000","unstructured":"Pierson, T., McArthur, J. & Siliciano, R. F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 18, 665\u2013708 (2000).","journal-title":"Annu. Rev. Immunol."},{"key":"801_CR67","first-page":"125","volume":"2","author":"AH Cohen","year":"1989","unstructured":"Cohen, A. H., Sun, N. C., Shapshak, P. & Imagawa, D. T. Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod. Pathol. 2, 125\u2013128 (1989).","journal-title":"Mod. Pathol."},{"key":"801_CR68","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1097\/QAD.0000000000000757","volume":"29","author":"M Blasi","year":"2015","unstructured":"Blasi, M. et al. Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine. AIDS 29, 1651\u20131657 (2015).","journal-title":"AIDS"},{"key":"801_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12941-019-0326-9","volume":"18","author":"ML Mzingwane","year":"2019","unstructured":"Mzingwane, M. L. et al. Detection and molecular characterization of urinary tract HIV-1 populations. Ann. Clin. Microbiol. Antimicrob. 18, 27 (2019).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"801_CR70","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1681\/ASN.2013050564","volume":"25","author":"G Canaud","year":"2014","unstructured":"Canaud, G. et al. The kidney as a reservoir for HIV-1 after renal transplantation. J. Am. Soc. Nephrol. 25, 407\u2013419 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR71","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1056\/NEJMc1910189","volume":"382","author":"M Blasi","year":"2020","unstructured":"Blasi, M. et al. Detection of donor\u2019s HIV strain in HIV-positive kidney transplant recipient. N. Engl. J. Med. 382, 195\u2013197 (2020).","journal-title":"N. Engl. J. Med."},{"key":"801_CR72","doi-asserted-by":"publisher","first-page":"113053","DOI":"10.1016\/j.celrep.2023.113053","volume":"42","author":"C Dufour","year":"2023","unstructured":"Dufour, C. et al. Near full-length HIV sequencing in multiple tissues collected postmortem reveals shared clonal expansions across distinct reservoirs during ART. Cell Rep. 42, 113053 (2023).","journal-title":"Cell Rep."},{"key":"801_CR73","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841\u2013845 (2010).","journal-title":"Science"},{"key":"801_CR74","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","volume":"128","author":"S Tzur","year":"2010","unstructured":"Tzur, S. et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128, 345\u2013350 (2010).","journal-title":"Hum. Genet."},{"key":"801_CR75","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41581-022-00538-3","volume":"18","author":"P Daneshpajouhnejad","year":"2022","unstructured":"Daneshpajouhnejad, P., Kopp, J. B., Winkler, C. A. & Rosenberg, A. Z. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat. Rev. Nephrol. 18, 307\u2013320 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"801_CR76","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.semnephrol.2015.04.008","volume":"35","author":"PD Dummer","year":"2015","unstructured":"Dummer, P. D. et al. APOL1 kidney disease risk variants: an evolving landscape. Semin. Nephrol. 35, 222\u2013236 (2015).","journal-title":"Semin. Nephrol."},{"key":"801_CR77","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1681\/ASN.2011040388","volume":"22","author":"JB Kopp","year":"2011","unstructured":"Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129\u20132137 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR78","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1681\/ASN.2014050469","volume":"26","author":"AN Kasembeli","year":"2015","unstructured":"Kasembeli, A. N. et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J. Am. Soc. Nephrol. 26, 2882\u20132890 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR79","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2215\/CJN.07490715","volume":"11","author":"MG Atta","year":"2016","unstructured":"Atta, M. G. et al. Association of APOL1 genotype with renal histology among black HIV-positive patients undergoing kidney biopsy. Clin. J. Am. Soc. Nephrol. 11, 262\u2013270 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"801_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275949","volume":"17","author":"A Abdu","year":"2022","unstructured":"Abdu, A. et al. High risk APOL1 genotypes and kidney disease among treatment na\u00efve HIV patients at Kano, Nigeria. PLoS One 17, e0275949 (2022).","journal-title":"PLoS One"},{"key":"801_CR81","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ekir.2022.01.1054","volume":"7","author":"RKY Hung","year":"2022","unstructured":"Hung, R. K. Y. et al. Genetic variants of APOL1 are major determinants of kidney failure in people of African ancestry with HIV. Kidney Int. Rep. 7, 786\u2013796 (2022).","journal-title":"Kidney Int. Rep."},{"key":"801_CR82","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40620-022-01512-9","volume":"36","author":"B Waziri","year":"2023","unstructured":"Waziri, B., Raji, Y. E., Ekrikpo, U. E. & Naicker, S. Apolipoprotein L1 gene variants and kidney disease in patients with HIV: a systematic review and meta-analysis. J. Nephrol. 36, 1119\u20131134 (2023).","journal-title":"J. Nephrol."},{"key":"801_CR83","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1681\/ASN.2011060562","volume":"23","author":"DM Fine","year":"2012","unstructured":"Fine, D. M. et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J. Am. Soc. Nephrol. 23, 343\u2013350 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR84","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/QAI.0000000000001010","volume":"73","author":"Purswani","year":"2016","unstructured":"Purswani et al. Pediatric HIVAIDS Cohort Study. Brief report: APOL1 renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. J. Acquir. Immune Defic. Syndr. 73, 63\u201368 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"801_CR85","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ekir.2019.04.002","volume":"4","author":"PM Ekulu","year":"2019","unstructured":"Ekulu, P. M. et al. APOL1 risk genotypes are associated with early kidney damage in children in Sub-Saharan Africa. Kidney Int. Rep. 4, 930\u2013938 (2019).","journal-title":"Kidney Int. Rep."},{"key":"801_CR86","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1159\/000332378","volume":"34","author":"DM Behar","year":"2011","unstructured":"Behar, D. M. et al. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am. J. Nephrol. 34, 452\u2013459 (2011).","journal-title":"Am. J. Nephrol."},{"key":"801_CR87","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrneph.2011.52","volume":"7","author":"S Rosset","year":"2011","unstructured":"Rosset, S., Tzur, S., Behar, D. M., Wasser, W. G. & Skorecki, K. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nat. Rev. Nephrol. 7, 313\u2013326 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"801_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051546","volume":"7","author":"DB Johnstone","year":"2012","unstructured":"Johnstone, D. B. et al. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS One 7, e51546 (2012).","journal-title":"PLoS One"},{"key":"801_CR89","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2017.07.003","volume":"37","author":"DJ Friedman","year":"2017","unstructured":"Friedman, D. J. A brief history of APOL1: a gene evolving. Semin. Nephrol. 37, 508\u2013513 (2017).","journal-title":"Semin. Nephrol."},{"key":"801_CR90","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1073\/pnas.1522913113","volume":"113","author":"OA Olabisi","year":"2016","unstructured":"Olabisi, O. A. et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc. Natl Acad. Sci. USA 113, 830\u2013837 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"801_CR91","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fmed.2018.00177","volume":"5","author":"SJ Rednor","year":"2018","unstructured":"Rednor, S. J. & Ross, M. J. Molecular mechanisms of injury in HIV-associated nephropathy. Front. Med. 5, 177 (2018).","journal-title":"Front. Med."},{"key":"801_CR92","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nm.4287","volume":"23","author":"P Beckerman","year":"2017","unstructured":"Beckerman, P. et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat. Med. 23, 429\u2013438 (2017).","journal-title":"Nat. Med."},{"key":"801_CR93","doi-asserted-by":"publisher","first-page":"dmm048952","DOI":"10.1242\/dmm.048952","volume":"14","author":"GM McCarthy","year":"2021","unstructured":"McCarthy, G. M. et al. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease. Dis. Model. Mech. 14, dmm048952 (2021).","journal-title":"Dis. Model. Mech."},{"key":"801_CR94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.ackd.2009.08.013","volume":"17","author":"RC Kalayjian","year":"2010","unstructured":"Kalayjian, R. C. The treatment of HIV-associated nephropathy. Adv. Chronic Kidney Dis. 17, 59\u201371 (2010).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"801_CR95","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/cid\/ciu765","volume":"60","author":"MM Estrella","year":"2015","unstructured":"Estrella, M. M. et al. The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin. Infect. Dis. 60, 646\u2013652 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"801_CR96","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.2215\/CJN.01330214","volume":"9","author":"BI Freedman","year":"2014","unstructured":"Freedman, B. I. & Skorecki, K. Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin. J. Am. Soc. Nephrol. 9, 2006\u20132013 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"801_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-021-00427-y","volume":"19","author":"C Danwang","year":"2022","unstructured":"Danwang, C., Noubiap, J. J., Robert, A. & Yombi, J. C. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res. Ther. 19, 3 (2022).","journal-title":"AIDS Res. Ther."},{"key":"801_CR98","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S2352-3018(22)00097-2","volume":"9","author":"S Bertagnolio","year":"2022","unstructured":"Bertagnolio, S. et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 9, e486\u2013e495 (2022).","journal-title":"Lancet HIV."},{"key":"801_CR99","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.kint.2021.07.015","volume":"100","author":"RM May","year":"2021","unstructured":"May, R. M. et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int. 100, 1303\u20131315 (2021).","journal-title":"Kidney Int."},{"key":"801_CR100","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41581-020-0332-3","volume":"16","author":"JC Velez","year":"2020","unstructured":"Velez, J. C., Caza, T. & Larsen, C. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat. Rev. Nephrol. 16, 565\u2013567 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"801_CR101","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1681\/ASN.2020060804","volume":"32","author":"AA Shetty","year":"2021","unstructured":"Shetty, A. A. et al. COVID-19-associated glomerular disease. J. Am. Soc. Nephrol. 32, 33 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR102","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1681\/ASN.2020050558","volume":"31","author":"HL Wu","year":"2020","unstructured":"Wu, H. L. et al. Acute kidney injury and collapsing glomerulopathy associated with COVID-19 and APOL1 high risk genotype. J. Am. Soc. Nephrol. 31, 1688\u20131695 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR103","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.ekir.2022.09.027","volume":"7","author":"G Giannini","year":"2022","unstructured":"Giannini, G. et al. Renal prognosis of COVID-19 associated nephropathy. Kidney Int. Rep. 7, 2722\u20132725 (2022).","journal-title":"Kidney Int. Rep."},{"key":"801_CR104","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1681\/ASN.2021070931","volume":"32","author":"S Kudose","year":"2021","unstructured":"Kudose, S. et al. Longitudinal outcomes of COVID-19-associated collapsing glomerulopathy and other podocytopathies. J. Am. Soc. Nephrol. 32, 2958\u20132969 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR105","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. https:\/\/www.who.int\/publications\/i\/item\/9789240031593 (World Health Organization, 2021; accessed January 2023)."},{"key":"801_CR106","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/hiv.12296","volume":"16","author":"R Acquah","year":"2015","unstructured":"Acquah, R., Graham, H. & Winter, A. Quantifying polypharmacy in a large HIV-infected cohort. HIV Med. 16, 583\u2013584 (2015).","journal-title":"HIV Med."},{"key":"801_CR107","first-page":"618","volume":"41","author":"C Bastida","year":"2017","unstructured":"Bastida, C. et al. Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population. Farm. Hosp. 41, 618\u2013624 (2017).","journal-title":"Farm. Hosp."},{"key":"801_CR108","first-page":"377","volume":"14","author":"SD Cohen","year":"2017","unstructured":"Cohen, S. D., Kopp, J. B. & Kimmel, P. L. Kidney diseases associated with human immunodeficiency virus infection. N. Engl. J. Med. 14, 377 (2017). Erratum in: N. Engl. J. Med. 378, 1657 (2018).","journal-title":"N. Engl. J. Med."},{"key":"801_CR109","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jinf.2017.01.010","volume":"74","author":"L Hamzah","year":"2017","unstructured":"Hamzah, L. et al. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate. J. Infect. 74, 492\u2013500 (2017).","journal-title":"J. Infect."},{"key":"801_CR110","first-page":"114","volume":"19","author":"JM Irizarry-Alvarado","year":"2009","unstructured":"Irizarry-Alvarado, J. M., Dwyer, J. P., Brumble, L. M., Alvarez, S. & Mensez, J. C. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read. 19, 114\u2013121 (2009).","journal-title":"AIDS Read."},{"key":"801_CR111","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40360-016-0100-y","volume":"17","author":"K Iwata","year":"2016","unstructured":"Iwata, K., Nagata, M., Watanabe, S. & Nishi, S. Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report. BMC Pharm. Toxicol. 17, 52 (2016).","journal-title":"BMC Pharm. Toxicol."},{"key":"801_CR112","first-page":"354908","volume":"2011","author":"B Fernandez-Fernandez","year":"2011","unstructured":"Fernandez-Fernandez, B. et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res. Treat. 2011, 354908 (2011).","journal-title":"AIDS Res. Treat."},{"key":"801_CR113","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(15)00211-8","volume":"3","author":"A Mocroft","year":"2016","unstructured":"Mocroft, A. et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international Cohort Study. Lancet HIV. 3, e23\u2013e32 (2016).","journal-title":"Lancet HIV."},{"key":"801_CR114","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper, R. D. et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin. Infect. Dis. 51, 496\u2013505 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"801_CR115","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.antiviral.2017.01.014","volume":"140","author":"KM Stray","year":"2017","unstructured":"Stray, K. M. et al. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures. Antivir. Res. 140, 116\u2013120 (2017).","journal-title":"Antivir. Res."},{"key":"801_CR116","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008046","volume":"96","author":"TK Novick","year":"2017","unstructured":"Novick, T. K. et al. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report. Medicine 96, e8046 (2017).","journal-title":"Medicine"},{"key":"801_CR117","doi-asserted-by":"publisher","first-page":"814","DOI":"10.7326\/L18-0592","volume":"170","author":"NC Bahr","year":"2019","unstructured":"Bahr, N. C. & Yarlagadda, S. G. Fanconi syndrome and tenofovir alafenamide: a case report. Ann. Intern. Med. 170, 814 (2019).","journal-title":"Ann. Intern. Med."},{"key":"801_CR118","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/QAI.0000000000001186","volume":"74","author":"FA Post","year":"2017","unstructured":"Post, F. A. et al. Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. J. Acquir. Immune Defic. Syndr. 74, 180 (2017).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"801_CR119","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/QAD.0000000000002699","volume":"34","author":"V Pilkington","year":"2020","unstructured":"Pilkington, V. et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14894 patients across 14 trials. AIDS 34, 2259\u20132268 (2020).","journal-title":"AIDS"},{"key":"801_CR120","doi-asserted-by":"publisher","first-page":"3","DOI":"10.24875\/AIDSRev.M17000010","volume":"20","author":"J Burgos","year":"2018","unstructured":"Burgos, J., Ribera, E. & Falco, V. Antiretroviral therapy in advanced HIV disease: which is the best regimen? AIDS Rev. 20, 3\u201313 (2018).","journal-title":"AIDS Rev."},{"key":"801_CR121","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11904-016-0315-y","volume":"13","author":"AC Achhra","year":"2016","unstructured":"Achhra, A. C., Nugent, M., Mocroft, A., Ryom, L. & Wyatt, C. M. Chronic kidney disease and antiretroviral therapy in HIV-positive individuals: recent developments. Curr. HIV\/AIDS Rep. 13, 149\u2013157 (2016).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"801_CR122","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/QAD.0000000000000563","volume":"29","author":"MF Chughlay","year":"2015","unstructured":"Chughlay, M. F. et al. Acute interstitial nephritis caused by lopinavir\/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis. AIDS 29, 503\u2013504 (2015).","journal-title":"AIDS"},{"key":"801_CR123","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/cid\/cis621","volume":"55","author":"Y Hamada","year":"2012","unstructured":"Hamada, Y. et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin. Infect. Dis. 55, 1262\u20131269 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"801_CR124","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00428-007-0418-3","volume":"450","author":"S Schmid","year":"2007","unstructured":"Schmid, S. et al. Acute interstitial nephritis of HIV positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch. 450, 665\u2013670 (2007).","journal-title":"Virchows Arch."},{"key":"801_CR125","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/QAD.0000000000001353","volume":"31","author":"S Jose","year":"2017","unstructured":"Jose, S. et al. Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. AIDS 31, 485\u2013492 (2017).","journal-title":"AIDS"},{"key":"801_CR126","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/QAI.0b013e3182a97c39","volume":"64","author":"SK Gupta","year":"2013","unstructured":"Gupta, S. K., Mi, D., Moe, S. M., Dub\u00e9, M. P. & Liu, Z. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J. Acquir. Immune Defic. Syndr. 64, 279\u2013283 (2013).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"801_CR127","first-page":"434","volume":"32","author":"J Milburn","year":"2016","unstructured":"Milburn, J., Jones, R. & Levy, J. B. Renal effects of novel antiretroviral drugs. Nephrol. Dial. Transpl. 32, 434\u2013439 (2016).","journal-title":"Nephrol. Dial. Transpl."},{"key":"801_CR128","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40265-013-0160-x","volume":"74","author":"ED Deeks","year":"2014","unstructured":"Deeks, E. D. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs 74, 195\u2013206 (2014).","journal-title":"Drugs"},{"key":"801_CR129","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/COH.0000000000000468","volume":"13","author":"V Spagnuolo","year":"2018","unstructured":"Spagnuolo, V., Castagna, A. & Lazzarin, A. Bictegravir. Curr. Opin. HIV AIDS 13, 326\u2013333 (2018).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"801_CR130","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.apsb.2016.07.013","volume":"6","author":"J Yin","year":"2016","unstructured":"Yin, J. & Wang, J. Renal drug transporters and their significance in drug\u2013drug interactions. Acta Pharm. Sin. B 6, 363\u2013373 (2016).","journal-title":"Acta Pharm. Sin. B"},{"key":"801_CR131","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","volume":"381","author":"F Raffi","year":"2013","unstructured":"Raffi, F. et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381, 735\u2013743 (2013).","journal-title":"Lancet"},{"key":"801_CR132","first-page":"256","volume":"41","author":"N Galizzi","year":"2018","unstructured":"Galizzi, N. et al. Glomerular filtration rate estimated by cystatin C formulas in HIV-1 patients treated with dolutegravir, rilpivirine or cobicistat. N. Microbiol. 41, 256\u2013261 (2018).","journal-title":"N. Microbiol."},{"key":"801_CR133","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa051871","volume":"354","author":"JE Gallant","year":"2006","unstructured":"Gallant, J. E. et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251\u2013260 (2006).","journal-title":"N. Engl. J. Med."},{"key":"801_CR134","first-page":"24S","volume":"33","author":"J Cutrell","year":"2016","unstructured":"Cutrell, J. & Bedimo, R. Single-tablet regimens in the treatment of HIV-1 infection. Fed. Pract. 33, 24S\u201330S (2016).","journal-title":"Fed. Pract."},{"key":"801_CR135","first-page":"44","volume":"40","author":"WR Truong","year":"2015","unstructured":"Truong, W. R., Schafer, J. J. & Short, W. R. Once-daily, single-tablet regimens for the treatment of HIV-1 infection. P T 40, 44\u201355 (2015).","journal-title":"P T"},{"key":"801_CR136","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/0956462418800865","volume":"30","author":"SM Michienzi","year":"2019","unstructured":"Michienzi, S. M., Schriever, C. A. & Badowski, M. E. Abacavir\/lamivudine\/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int. J. STD AIDS 30, 181\u2013187 (2019).","journal-title":"Int. J. STD AIDS"},{"key":"801_CR137","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3018(18)30296-0","volume":"6","author":"JJ Eron","year":"2019","unstructured":"Eron, J. J. et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3B trial. Lancet HIV. 6, e15\u2013e24 (2019).","journal-title":"Lancet HIV."},{"key":"801_CR138","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new (accessed March 2023)."},{"key":"801_CR139","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","volume":"83","author":"P Cahn","year":"2020","unstructured":"Cahn, P. et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J. Acquir. Immune Defic. Syndr. 83, 310\u2013318 (2020). Erratum in: J Acquir Immune Defic Syndr. 84, e21 (2020).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"801_CR140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fimmu.2021.637910","volume":"12","author":"BJ van Welzen","year":"2021","unstructured":"van Welzen, B. J., Oomen, P. G. A. & Hoepelman, A. I. M. Dual antiretroviral therapy-all quiet beneath the surface? Front. Immunol. 12, 12 (2021).","journal-title":"Front. Immunol."},{"key":"801_CR141","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/microorganisms10020433","volume":"10","author":"A P\u00e9rez-Gonz\u00e1lez","year":"2022","unstructured":"P\u00e9rez-Gonz\u00e1lez, A., Su\u00e1rez-Garc\u00eda, I., Ocampo, A. & Poveda, E. Two-drug regimens for HIV-current evidence, research gaps and future challenges. Microorganisms 10, 433 (2022).","journal-title":"Microorganisms"},{"key":"801_CR142","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.4049\/jimmunol.1600120","volume":"196","author":"CS Palmer","year":"2016","unstructured":"Palmer, C. S. et al. Emerging role and characterization of immunometabolism: relevance to HIV pathogenesis, serious non-AIDS events, and a cure. J. Immunol. 196, 4437\u20134444 (2016).","journal-title":"J. Immunol."},{"key":"801_CR143","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/jgs.12695","volume":"62","author":"M Greene","year":"2014","unstructured":"Greene, M., Steinman, M. A., McNicholl, I. R. & Valcour, V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J. Am. Geriatr. Soc. 62, 447\u2013453 (2014).","journal-title":"J. Am. Geriatr. Soc."},{"key":"801_CR144","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1046\/j.1523-1755.2003.00230.x","volume":"64","author":"A Wei","year":"2003","unstructured":"Wei, A. et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int. 64, 1462\u20131471 (2003).","journal-title":"Kidney Int."},{"key":"801_CR145","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","volume":"37","author":"DC Wheeler","year":"2022","unstructured":"Wheeler, D. C. et al. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol. Dial. Transpl. 37, 1647\u20131656 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"801_CR146","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/ki.2012.263","volume":"83","author":"MS Lipkowitz","year":"2013","unstructured":"Lipkowitz, M. S. et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 83, 114\u2013120 (2013).","journal-title":"Kidney Int."},{"key":"801_CR147","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrneph.2015.172","volume":"12","author":"BI Freedman","year":"2016","unstructured":"Freedman, B. I. & Cohen, A. H. Hypertension-attributed nephropathy: what\u2019s in a name? Nat. Rev. Nephrol. 12, 27\u201336 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"801_CR148","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/MNH.0000000000000816","volume":"31","author":"DJ Friedman","year":"2022","unstructured":"Friedman, D. J., Ma, L. & Freedman, B. I. Treatment potential in APOL1-associated nephropathy. Curr. Opin. Nephrol. Hypertens. 31, 442\u2013448 (2022).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"801_CR149","doi-asserted-by":"crossref","unstructured":"Zimmerman B., Dakin L., Fortier A. Small molecule APOL1 inhibitors block APOL1 pore function and reduce proteinuria in an APOL1-mediated kidney disease mouse model. J. Am. Soc. Nephrol. 2021. (Kidney Week Edition Abstract):419.","DOI":"10.1681\/ASN.20213210S1419a"},{"key":"801_CR150","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","volume":"388","author":"O Egbuna","year":"2023","unstructured":"Egbuna, O. et al. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N. Engl. J. Med. 388, 969\u2013979 (2023).","journal-title":"N. Engl. J. Med."},{"key":"801_CR151","doi-asserted-by":"crossref","unstructured":"Falk, R. et al. Design of a phase 2\/3 adaptive trail, AMPLITUDE, evaluating Inaxaplin in APOL1-mediated kidney disease. J. Am. Soc. Nephrol. (Suppl.) 33, Th-PO480 (2022).","DOI":"10.1681\/ASN.20223311S1181c"},{"key":"801_CR152","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ki.2014.270","volume":"87","author":"B Nichols","year":"2015","unstructured":"Nichols, B. et al. Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int. 87, 332\u2013342 (2015).","journal-title":"Kidney Int."},{"key":"801_CR153","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/MNH.0000000000000704","volume":"30","author":"LA Bruggeman","year":"2021","unstructured":"Bruggeman, L. A., Sedor, J. R. & O\u2019Toole, J. F. Apolipoprotein L1 and mechanisms of kidney disease susceptibility. Curr. Opin. Nephrol. Hypertens. 30, 317\u2013323 (2021).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"801_CR154","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.2019.9056","volume":"322","author":"JA Singh","year":"2019","unstructured":"Singh, J. A. Filgotinib, a JAK1 inhibitor, for treatment-resistant rheumatoid arthritis. JAMA 322, 309\u2013311 (2019).","journal-title":"JAMA"},{"key":"801_CR155","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126124","volume":"4","author":"M Aghajan","year":"2019","unstructured":"Aghajan, M. et al. Antisense oligonucleotide treatment ameliorates IFN-g-induced proteinuria in APOL1-transgenic mice. JCI Insight 4, e126124 (2019).","journal-title":"JCI Insight"},{"key":"801_CR156","first-page":"26464","volume":"80","author":"Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).","year":"2015","unstructured":"Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Organ procurement and transplantation: implementation of the HIV Organ Policy Equity Act. Final rule. Fed. Regist. 80, 26464\u201326467 (2015).","journal-title":"Fed. Regist."},{"key":"801_CR157","first-page":"435","volume":"30","author":"ME Roland","year":"2016","unstructured":"Roland, M. E. et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS 30, 435\u2013444 (2016).","journal-title":"AIDS"},{"key":"801_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-019-0253-z","volume":"16","author":"X Zheng","year":"2019","unstructured":"Zheng, X. et al. Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis. AIDS Res. Ther. 16, 37 (2019).","journal-title":"AIDS Res. Ther."},{"key":"801_CR159","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1001\/jamasurg.2021.6798","volume":"157","author":"Zarinsefat","year":"2022","unstructured":"Zarinsefat et al. Long-term outcomes following kidney and liver transplant in recipients with HIV. JAMA Surg. 157, 240\u2013247 (2022). Erratum in: JAMA Surg. (2022).","journal-title":"JAMA Surg."},{"key":"801_CR160","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1111\/ajt.12847","volume":"14","author":"Y Xia","year":"2014","unstructured":"Xia, Y. et al. Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am. J. Transpl. 14, 2037\u20132047 (2014).","journal-title":"Am. J. Transpl."},{"key":"801_CR161","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1681\/ASN.2014070726","volume":"26","author":"JE Locke","year":"2015","unstructured":"Locke, J. E. et al. A national study of outcomes among HIV-infected kidney transplant recipients. J. Am. Soc. Nephrol. 26, 2222\u20132229 (2015) .","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR162","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13532","volume":"33","author":"JF Camargo","year":"2019","unstructured":"Camargo, J. F. et al. Clinical outcomes in HIV+\/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience. Clin. Transpl. 33, e13532 (2019).","journal-title":"Clin. Transpl."},{"key":"801_CR163","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/SLA.0000000000001761","volume":"265","author":"JE Locke","year":"2017","unstructured":"Locke, J. E. et al. Survival benefit of kidney transplantation in HIV-infected patients. Ann. Surg. 265, 604\u2013608 (2017).","journal-title":"Ann. Surg."},{"key":"801_CR164","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMc0900837","volume":"362","author":"E Muller","year":"2010","unstructured":"Muller, E., Kahn, D. & Mendelson, M. Renal transplantation between HIV-positive donors and recipients. N. Engl. J. Med. 362, 2336\u20132337 (2010).","journal-title":"N. Engl. J. Med."},{"key":"801_CR165","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1056\/NEJMc1903013","volume":"381","author":"P Selhorst","year":"2019","unstructured":"Selhorst, P. et al. Longer-term outcomes of HIV-positive-to-HIV-positive renal transplantation. N. Engl. J. Med. 381, 1387\u20131389 (2019).","journal-title":"N. Engl. J. Med."},{"key":"801_CR166","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1681\/ASN.2017080853","volume":"29","author":"E Muller","year":"2018","unstructured":"Muller, E. & Barday, Z. HIV-positive kidney donor selection for HIV-positive transplant recipients. J. Am. Soc. Nephrol. 29, 1090\u20131095 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR167","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/ajt.16205","volume":"21","author":"CM Durand","year":"2021","unstructured":"Durand, C. M. et al. A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action. Am. J. Transpl. 21, 1754\u20131764 (2021).","journal-title":"Am. J. Transpl."},{"key":"801_CR168","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/bdd.1860","volume":"34","author":"L Frassetto","year":"2013","unstructured":"Frassetto, L. et al. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm. Drug. Dispos. 34, 442\u2013451 (2013).","journal-title":"Biopharm. Drug. Dispos."},{"key":"801_CR169","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1016\/j.bmcl.2009.07.118","volume":"19","author":"CA Flentge","year":"2009","unstructured":"Flentge, C. A. et al. Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs. Bioorg. Med. Chem. Lett. 19, 5444\u20135448 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"801_CR170","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1071\/SH11028","volume":"8","author":"AC Hearps","year":"2011","unstructured":"Hearps, A. C. et al. HIV infection and aging of the innate immune system. Sex. Health 8, 453\u2013464 (2011).","journal-title":"Sex. Health"},{"key":"801_CR171","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/j.1600-6143.2010.03258.x","volume":"10","author":"M Touzot","year":"2010","unstructured":"Touzot, M. et al. Renal transplantation in HIV-infected patients: the Paris experience. Am. J. Transpl. 10, 2263\u20132269 (2010).","journal-title":"Am. J. Transpl."},{"key":"801_CR172","first-page":"ii9","volume":"3","author":"E Rodrigo","year":"2010","unstructured":"Rodrigo, E. et al. Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and results. NDT Plus 3, ii9\u2013ii14 (2010).","journal-title":"NDT Plus"},{"key":"801_CR173","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/ajt.12142","volume":"13","author":"PV Chin-Hong","year":"2013","unstructured":"Chin-Hong, P. V. & Kwak, E. J. AST infectious diseases community of practice. human papillomavirus in solid organ transplantation. Am. J. Transpl. 13, 189\u2013200 (2013).","journal-title":"Am. J. Transpl."},{"key":"801_CR174","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1053\/j.ajkd.2011.10.050","volume":"59","author":"V Jotwani","year":"2012","unstructured":"Jotwani, V., Li, Y., Grunfeld, C., Choi, A. I. & Shlipak, M. G. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am. J. Kidney Dis. 59, 628\u2013635 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"801_CR175","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/hiv.12038","volume":"14","author":"L Ryom","year":"2013","unstructured":"Ryom, L. et al. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med. 14, 503\u2013508 (2013).","journal-title":"HIV Med."},{"key":"801_CR176","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1111\/ajt.14235","volume":"17","author":"AD Muzaale","year":"2017","unstructured":"Muzaale, A. D. et al. Risk of end-stage renal disease in HIV-positive potential live kidney donors. Am. J. Transpl. 17, 1823\u20131832 (2017).","journal-title":"Am. J. Transpl."},{"key":"801_CR177","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13171","volume":"21","author":"A Grupper","year":"2019","unstructured":"Grupper, A. et al. In sickness and in health: living HIV positive kidney donation from a wife to her husband, with 7 years\u2019 post-transplant follow-up. Transpl. Infect. Dis. 21, e13171 (2019).","journal-title":"Transpl. Infect. Dis."},{"key":"801_CR178","unstructured":"Johns Hopkins Medicine. First living donor HIV-to-HIV kidney transplant in the U.S. https:\/\/www.hopkinsmedicine.org\/news\/newsroom\/news-releases\/first-ever-living-donor-hiv-to-hiv-kidney-transplant-in-the-US (2019)."},{"key":"801_CR179","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1097\/TP.0000000000003093","volume":"104","author":"M Kapuriya","year":"2020","unstructured":"Kapuriya, M., Vaidya, A. & Rajkumar, V. Successful HIV-positive, live renal donor transplant. a unique method of expanding the donor pool. Transplantation 104, e140\u2013e141 (2020).","journal-title":"Transplantation"},{"key":"801_CR180","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4103\/ijn.ijn_229_21","volume":"32","author":"N Saldanha","year":"2022","unstructured":"Saldanha, N. et al. A preemptive living donor renal transplant in an HIV positive patient from an HIV positive donor. Indian J. Nephrol. 32, 375\u2013377 (2022).","journal-title":"Indian J. Nephrol."},{"key":"801_CR181","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1681\/ASN.2017060658","volume":"29","author":"MD Doshi","year":"2018","unstructured":"Doshi, M. D. et al. APOL1 genotype and renal function of black living donors. J. Am. Soc. Nephrol. 29, 1309\u20131316 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"801_CR182","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1600-6143.2011.03513.x","volume":"11","author":"AM Reeves-Daniel","year":"2011","unstructured":"Reeves-Daniel, A. M. et al. The APOL1 gene and allograft survival after kidney transplantation. Am. J. Transpl. 11, 1025\u20131030 (2011).","journal-title":"Am. J. Transpl."},{"key":"801_CR183","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/ajt.13502","volume":"16","author":"M Okumi","year":"2016","unstructured":"Okumi, M. et al. ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management. Am. J. Transpl. 16, 886\u2013896 (2016).","journal-title":"Am. J. Transpl."},{"key":"801_CR184","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1016\/j.transproceed.2020.07.008","volume":"52","author":"S Katou","year":"2020","unstructured":"Katou, S. et al. ABO-incompatible living donor kidney transplantation in a human immunodeficiency virus-positive recipient from a human immunodeficiency virus-positive donor: a case report. Transpl. Proc. 52, 2739\u20132741 (2020).","journal-title":"Transpl. Proc."},{"key":"801_CR185","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/TP.0b013e31817cf403","volume":"86","author":"M Campara","year":"2008","unstructured":"Campara, M. et al. ABO incompatible renal transplantation in an HIV-seropositive patient. Transplantation 86, 176\u2013178 (2008).","journal-title":"Transplantation"},{"key":"801_CR186","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S0140-6736(21)00084-2","volume":"397","author":"J Thornton","year":"2021","unstructured":"Thornton, J. Expanding HIV-positive organ donation. Lancet 397, 184\u2013185 (2021).","journal-title":"Lancet"},{"key":"801_CR187","doi-asserted-by":"publisher","first-page":"F13","DOI":"10.1097\/QAD.0000000000002000","volume":"32","author":"J Botha","year":"2018","unstructured":"Botha, J. et al. Living donor liver transplant from an HIV-positive mother to her HIV-negative child: opening up new therapeutic options. AIDS 32, F13\u2013F19 (2018).","journal-title":"AIDS"},{"key":"801_CR188","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13691","volume":"23","author":"MR Pereira","year":"2021","unstructured":"Pereira, M. R. et al. HIV transmission through living donor kidney transplant: an 11-year follow-up on the recipient and donor. Transpl. Infect. Dis. 23, e13691 (2021).","journal-title":"Transpl. Infect. Dis."},{"key":"801_CR189","unstructured":"Lin, S.-N. et al. Outcomes of solid organ transplantation from an HIV positive donor to negative recipients. Am J Transplant. https:\/\/atcmeetingabstracts.com\/abstract\/outcomes-of-solid-organ-transplantation-from-an-hiv-positive-donor-to-negative-recipients (2016)."},{"key":"801_CR190","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4103\/0971-4065.97135","volume":"22","author":"P Mukhopadhyay","year":"2012","unstructured":"Mukhopadhyay, P. et al. Transmission of human immunodeficiency virus infection by renal transplantation. Indian. J. Nephrol. 22, 133\u2013135 (2012).","journal-title":"Indian. J. Nephrol."},{"key":"801_CR191","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.transproceed.2010.05.026","volume":"42","author":"B Borchi","year":"2010","unstructured":"Borchi, B. et al. Case report: HIV infection from a kidney transplant. Transpl. Proc. 42, 2267\u20132269 (2010).","journal-title":"Transpl. Proc."},{"key":"801_CR192","doi-asserted-by":"publisher","first-page":"ofy225","DOI":"10.1093\/ofid\/ofy225","volume":"5","author":"B Fischetti","year":"2018","unstructured":"Fischetti, B. et al. Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment. Open. Forum Infect. Dis. 5, ofy225 (2018).","journal-title":"Open. Forum Infect. Dis."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00801-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00801-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00801-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T04:08:40Z","timestamp":1731125320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-023-00801-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":192,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1038\/s41581-023-00801-1","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"29 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}